Additionally, PPAR agonists attenuate platelet activation; an important discovery for two reasons.First, activated platelets are formidable antagonists that initiate and prolong a cascade of events that contribute tocardiovascular disease (CVD) progression. The gene discussed is PPARA; the disease is glycogen storage disease VI.